- Home
- HR vs MIRM Comparison
HR vs MIRM Comparison
Compare HR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HR | MIRM |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.7B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HR | MIRM |
|---|---|---|
| Price | $19.96 | $101.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $19.29 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 4.6M | 1.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | 60.77 | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,180,546,000.00 | $19,138,000.00 |
| Revenue This Year | N/A | $26.22 |
| Revenue Next Year | $3.14 | $22.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.09 | $43.50 |
| 52 Week High | $20.61 | $114.99 |
Technical Indicators
Market Signals| Indicator | HR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 51.95 |
| Support Level | $17.38 | $95.68 |
| Resistance Level | $20.46 | $107.51 |
| Average True Range (ATR) | 0.32 | 5.22 |
| MACD | -0.10 | -0.65 |
| Stochastic Oscillator | 28.98 | 33.42 |
Price Performance
Historical ComparisonAbout HR Healthcare Realty Trust Incorporated
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.